HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer

Oncoscience

Volumn 2, Issue 3, 2015, Pages 207-224

  Chandran, Vineesh Indira ^a   Eppenberger Castori, Serenella ^b   Venkatesh, Thejaswini ^c   Vine, Kara Lea ^d   Ranson, Marie ^d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NITTE UNIVERSITY   (India)

^d UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Co amplification; Co overexpression; Correlation; HER2 positive breast cancer; HER2 ERBB2; UPAR PLAUR

Indexed keywords

EID: 84947616846     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.146     Document Type: Article

References (165)

1. Higgins MJ and Baselga J. Targeted therapies for breast cancer. The Journal of Clinical Investigation. 2011; 121: 3797-3803.
2. Heiser LM, Sadanandam A, Kuo W-L, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109: 2724-9.
3. Johnston SR. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. European Journal of Cancer. 2011; 47: S38-S47.
4. Weigelt B, Peterse JL, and van 't Veer LJ. Breast cancer metastasis: markers and models. Nature Reviews Cancer. 2005; 5: 591-602.
5. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, and Bast RCJ. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology. 2007; 25: 5287-5312.
6. Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, and Harbeck N. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. Journal of Clinical Oncology. 2003; 21: 1022-1028.
7. Lund IK, Illemann M, Thurison T, Christensen IJ, and Høyer-Hansen G. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibodybased therapy. Current Drug Targets. 2011; 12: 1744-1760.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987; 235: 177-182.
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, and Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-712.
10. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology. 1997; 15: 2894-2904.
11. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, and Bernstein L. Evaluation of HER-2/neu gene amplification and over-expression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. Journal of Clinical Oncology. 2002; 20: 3095-3105.
12. Leonard DS, Hill AD, Kelly L, Dijkstra B, McDermott E, and O'Higgins NJ. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. British Journal of Surgery. 2002; 89: 262-271.
13. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, and Lundin J. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population based study. Clinical Cancer Research. 2003; 9: 923-930.
14. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, and Ghani F. Clinical utility of serum HER2/neu in monitoring and prediction of progressionfree survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Research. 2005; 7: R436-R443.
15. Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F, Fink D, Dieterich H, Hohl M, Müller H, Paris K, Schoumacher F, and Eppenberger U. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. Journal of Clinical Oncology. 2001; 19: 645-656.
16. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, and Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237: 178-182.
17. Liu Y, el-Ashry D, Chen D, Ding IY, and Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogendepleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Research and Treatment. 1995; 34: 97-117.
18. Tan M, Yao J, and Yu D. Overexpression of the cerbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Research. 1997; 57: 1199-1205.
19. O'Charoenrat P, Rhys-Evans P, Court WJ, Box GM, and Eccles SA. Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands. Clinical and Experimental Metastasis. 1999; 17: 631-639.
20. Kerbel RS, Viloria-Petit A, Klement G, and Rak J. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. European Journal of Cancer. 2000; 36: 1248-1257.
21. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, and Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nature Cell Biology. 2001; 3: 785-792.
22. Zhou BP, Li Y, and Hung MC. HER2/Neu signaling and therapeutic approaches in breast cancer. Breast Disease. 2002; 15: 13-24.
23. Feldner JC and Brandt BH. Cancer cell motility-on the road from c-erbB-2 receptor steered signaling to actin reorganization. Experimental Cell Research. 2002; 272: 93-108.
24. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zänker KS, and Brandt BH. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB Journal. 2002; 16: 1823-1825.
25. Menard S, Casalini P, Campiglio M, Pupa SM, and Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cellular and Molecular Life Sciences. 2004; 61: 2965-2978.
26. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, and Henderson IC. c-erbB-2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. New England Journal of Medicine. 1994; 330: 1260-1266.
27. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, and Liu ET. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute. 1998; 90: 1346-1360.
28. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, and Wolmark N. erbB-2 and response to doxorubicin in patients with axillary lymph nodepositive, hormone receptor-negative breast cancer. Journal of the National Cancer Institute. 1998; 90: 1361-1370.
29. Niehans GA, Singleton TP, Dykoski D, and Kiang DT. Stability of HER-2/neu expression over time and at multiple metastatic sites. Journal of the National Cancer Institute. 1993; 85: 1230-1235.
30. Nahta R, Yu D, Hung M, Hortobagyi GN, and Esteva FJ. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology. 2006a; 3: 269-280.
31. Nahta R and Esteva FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Research. 2006b; 8: 215.
32. Pierga J-Y, Bonneton C, Magdelénat H, Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery J-P, and Cremoux Pd. Real-time quantitative PCR determination of urokinasetype plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. International Journal of Cancer. 2005; 114: 291-298.
33. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, et al. UPAR and HER2 gene status in individual breast cancer cells from blood and tissues. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103: 17361-17365.
34. Tan M, Li P, Sun M, Yin G, and Yu D. Upregulation and activation of PKC by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC and Src inhibitors. Oncogene. 2006; 25: 3286-3295.
35. Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, and Eppenberger-Castori S. Increased expression of urokinasetype plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. Journal of Clinical Oncology. 2006; 24: 4245-4253.
36. Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl P-O, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, et al. Identification of Subtypes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome. Journal of Clinical Oncology. 2010; 28: 1813-1820.
37. Berg D, Wolff C, Malinowsky K, Tran K, Walch A, Bronger H, Schuster T, Höfler H, and Becker KF. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. Journal of Cellular Physiology. 2012; 227: 204-212.
38. Markiewicz A, Ksiazkiewicz M, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Szade J, and Zaczek AJ. Mesenchymal Phenotype of CTC-Enriched Blood Fraction and Lymph Node Metastasis Formation Potential. PLoS ONE. 2014; 9: e93901.
39. Velasco-Velazquez MA, Popov VM, Lisanti MP, and Pestell RG. The role of breast cancer stem cells in metastasis and therapeutic implications. The American Journal of Pathology. 2011b; 179: 2-11.
40. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, et al. Molecular portraits of human breast tumors. Nature. 2000; 406: 747-752.
41. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 10869-10874.
42. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 8418-8423.
43. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7.
44. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology. 2009; 27: 1160-1167.
45. Weigelt B, Baehner FL, and Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. The Journal of Pathology. 2010; 220: 263-280.
46. Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, and Bertucci F. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Molecular Cancer. 2014; 13: 228.
47. Prat A and Perou CM. Deconstructing the molecular portraits of breast cancer. Molecular Oncology. 2011; 5: 5-23.
48. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, and Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research. 2010; 12: R68.
49. Eroles P, Bosch A, Pérez-Fidalgo JA, and Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews. 2012; 38: 698-707.
50. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, and Gelmon K. Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology. 2010; 28: 3271-3277.
51. Cadoo KA, Fornier MN, and Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2013; 57: 312-321.
52. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, and Norton L. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine. 2001; 344: 783-792.
53. Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, and DiPiro PJ. Metastatic patterns of breast cancer subtypes: What radiologists should know in the era of personalized cancer medicine. Clinical Radiology. 2015; 70: 1-10.
54. Morrow M. Personalizing extent of breast cancer surgery according to molecular subtypes. The Breast. 2013; 22, Supplement 2: S106-S109.
55. Ursini-Siegel J, Schade B, Cardiff RD, and Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews Cancer. 2007; 7: 389-397.
56. Feigin ME and Muthuswamy SK. ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Experimental Cell Research. 2009; 315: 707-716.
57. Hynes NE and MacDonald G. ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology. 2009; 21: 177-184.
58. Ranson M and Andronicos NM. Plasminogen binding and cancer: promises and pitfalls. Frontiers in Bioscience 2003; 8: s294-304.
59. Carriero MV, Franco P, Votta G, Longanesi-Cattani I, Vento MT, Masucci MT, Mancini A, Caputi M, Iaccarino I, and Stoppelli MP. Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors. Current Drug Targets. 2011; 12: 1761-1771.
60. Carriero MV and Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Current Pharmaceutical Design. 2011; 17: 1944-1961.
61. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, and Smith HS. The Urokinase Receptor Is Expressed in Invasive Breast Cancer but not in Normal Breast Tissue. Cancer Research. 1994; 54: 861-866.
62. LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, and Craik CS. Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer. Cancer Research. 2013; 73: 2070-2081.
63. Giannopoulou I, Mylona E, Kapranou A, Mavrommatis J, Markaki S, Zoumbouli Ch, Keramopoulos A, and Nakopoulou L. The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. Cancer Letters. 2007; 246: 262-267.
64. O'Halloran TV, Ahn R, Hankins P, Swindell E, and Mazar AP. The Many Spaces of uPAR: Delivery of Theranostic Agents and Nanobins to Multiple Tumor Compartments through a Single Target. Theranostics. 2013; 3: 496-506.
65. DanØ K, RØMer J, Nielsen BS, BjØRn S, Pyke C, Rygaard J, and Lund LR. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. acta pathologica, microbiologica, et immunologica Scandinavica. 1999; 107: 120-127.
66. Suzuki S, Hayashi Y, Wang Y, Nakamura T, Morita Y, Kawasaki K, Ohta K, Aoyama N, Kim SR, Itoh H, Kuroda Y, and Doe WF. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut. 1998; 43: 798-805.
67. Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R, and Gonias SL. Cell Signaling by Urokinase-type Plasminogen Activator Receptor Induces Stem Cell-like Properties in Breast Cancer Cells. Cancer Research. 2010; 70: 8948-8958.
68. Bempt IV, Drijkoningen M, and De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Current Opinion in Oncology. 2007; 19: 552-557.
69. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery. 2012; 2: 401-404.
70. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, and Schultz N. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling. 2013; 6: pl1.
71. Johnson MD, Torri JA, Lippman ME, and Dickson RB. Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness. Experimental Cell Research. 1999; 247: 105-113.
72. Boyd DD, Wang H, Avila H, Parikh NU, Kessler H, Magdolen V, and Gallick GE. Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clinical Cancer Research. 2004; 10: 1545-1555.
73. Xu J and Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Molecular Endocrinology. 2003; 17: 1681-1692.
74. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S, Hill AD, and Young LS. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008; 27: 3021-3031.
75. Myers E, Hill AD, Kelly G, McDermott EW, O'Higgins NJ, Buggy Y, and Young LS. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, andNCoRin breast cancer. Clinical Cancer Research 2005; 11: 2111-2122.
76. Goel A and Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators,the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. Journal of Biological Chemistry. 2004; 279: 14909-14916.
77. Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O'Higgins NJ, Hill AD, and Young LS. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. Journal of Clinical Pathology 2004; 57: 1069-1074.
78. Qin L, Liao L, Redmond A, Young L, Yuan Y, Chen H, O'Malley BW, and Xu J. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Molecular and Cellular Biology. 2008; 28: 5937-5950.
79. Louie MC, Revenko AS, Zou JX, Yao J, and Chen HW. Direct control of cell cycle gene expression by protooncogene product ACTR, and its autoregulation underlies its transforming activity. Molecular and Cellular Biology. 2006; 26: 3810-3823.
80. Mussi P, Yu C, O'Malley BW, and Xu J. Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Molecular Endocrinology. 2006; 20: 3105-3119.
81. Yuan Y, Qin L, Liu D, Wu RC, Mussi P, Zhou S, Songyang Z, and Xu J. Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression. Cancer Research. 2007; 67: 8032-8042.
82. Wang S, Yuan Y, Liao L, Kuang S-Q, Tien JC-Y, O'Malley BW, and Xu J. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106: 151-156.
83. Fleming FJ, Hill AD, McDermott EW, O'Higgins NJ, and Young LS. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. Journal of Clinical Endocrinology and Metabolism. 2004; 89: 375-383.
84. Muthuswamy SK and Muller WJ. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Oncogene. 1995; 11: 1801-1810.
85. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, and Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6: 117-127.
86. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, and Yu D. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Research. 2005; 65: 1858-1867.
87. Xu Y, Hu B, Qin L, Zhao L, Wang Q, Wang Q, Xu Y, and Jiang J. SRC-1 and Twist1 Expression Positively Correlates with a Poor Prognosis in Human Breast Cancer. International Journal of Biological Sciences. 2014; 10: 396-403.
88. Guerrero J, Santibañez JF, González A, and Martínez J. EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Experimental Cell Research. 2004; 292: 201-208.
89. Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, and Messing RO. Protein kinase C isozymes and the regulation of diverse cell responses. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2000; 279: L429-L438.
90. Parker PJ and Murray-Rust J. PKC at a glance. Journal of Cell Science. 2004; 117: 131-132.
91. Morse-Gaudio M, Connolly JM, and Rose DP. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. International Journal of Oncology. 1998; 12: 1349-1354.
92. Masur K, Lang K, Niggemann B, Zanker KS, and Entschladen F. High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Molecular Biology of the Cell 2001; 12: 1973-1982.
93. Lahn M, Köhler G, Sundell K, Su C, Li S, Paterson BM, and Bumol TF. Protein kinase C alpha expression in breast and ovarian cancer. Oncology. 2004; 67: 1-10.
94. Michie AM and Nakagawa R. The link between PKCalpha regulation and cellular transformation. Immunology Letters. 2005; 96: 155-162.
95. Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, and Parker PJ. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. The Journal of Clinical Investigation. 1995; 95: 1906-1915.
96. Lønne GK, Cornmark L, Zahirovic IO, Landberg G, Jirström K, and Larsson C. PKCa expression is a marker for breast cancer aggressiveness. Molecular Cancer. 2010; 9.
97. Peles E, Levy RB, Or E, Ullrich A, and Yarden Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J. 1991; 10: 2077-2086.
98. Magnifico A, Albano L, Campaner S, Campiglio M, Pilotti S, Ménard S, and Tagliabue E. Protein Kinase Ca Determines HER2 Fate in Breast Carcinoma Cells with HER2 Protein Overexpression without Gene Amplification. Cancer Research. 2007; 67: 5308-5317.
99. Busso N, Masur SK, Lazega D, Waxman S, and Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. Journal of Cell Biology. 1994; 126: 259-270.
100. Sliva D, English D, Lyons D, and Lloyd FPJ. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochemical and Biophysical Research Communications. 2002; 290: 552-557.
101. Merkhofer EC, Cogswell P, and Baldwin AS. Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene. 2010; 29: 1238-1248.
102. Cogswell PC, Guttridge DC, Funkhouser WK, and Baldwin ASJ. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 2000; 19: 1123-1131.
103. Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, Ju X, Ojeifo J, Jiao X, Yeow WS, Katiyar S, Shirley LA, Joyce D, Lisanti MP, et al. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Research. 2010; 70: 10464-10473.
104. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1: 555-567.
105. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP, and Pelicci PG. The tumor suppressor p53 regulates polarity of selfrenewing divisions in mammary stem cells. Cell. 2009; 138: 1083-1095.
106. Korkaya H, Paulson A, Iovino F, and Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008; 27: 6120-6130.
107. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, and Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New England Journal of Medicine. 1987; 316: 1435-1440.
108. Stockler M, Wilcken NR, Ghersi D, and Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews. 2000; 26: 151-168.
109. Lippman ME. High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. New England Journal of Medicine. 2000; 342: 1119-1120.
110. Reya T, Morrison SJ, Clarke MF, and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-111.
111. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, and Jensen LJ. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research. 2013; 41: D808-D815.
112. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, and Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Molecular and Cellular Biology. 1996; 16: 5276-5287.
113. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, and Greene MI. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 1989; 58: 287-292.
114. Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ, Kim JH, Kim SW, Ryu HS, Park IA, Im SA, Gong G, Jung KH, Kim HJ, et al. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. British Journal of Cancer. 2014.
115. Liu D, Aguirre Ghiso J, Estrada Y, and Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell. 2002; 1: 445-457.
116. Jo M, Thomas KS, O'Donnell DM, and Gonias SL. Epidermal Growth Factor Receptor-dependent and-independent Cell-signaling Pathways Originating from the Urokinase Receptor. Journal of Biological Chemistry. 2003; 278: 1642-1646.
117. Monaghan-Benson E and McKeown-Longo PJ. Urokinasetype Plasminogen Activator Receptor Regulates a Novel Pathway of Fibronectin Matrix Assembly Requiring Srcdependent Transactivation of Epidermal Growth Factor Receptor. Journal of Biological Chemistry. 2006; 281: 9450-9459.
118. Jo M, Thomas KS, Takimoto S, Gaultier A, Hsieh EH, Lester RD, and Gonias SL. Urokinase receptor primes cells to proliferate in response to epidermal growth factor. Oncogene. 2006; 26: 2585-2594.
119. D'Alessio S, Gerasi L, and Blasi F. uPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro. Journal of Cell Science. 2008; 121: 3922-3932.
120. Hu J, Jo M, Cavenee WK, Furnari F, VandenBerg SR, and Gonias SL. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108: 15984-15989.
121. Chumbalkar V, Latha K, Hwang YH, Maywald R, Hawley L, Sawaya R, Diao L, Baggerly K, Cavenee WK, Furnari FB, and Bogler O. Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of ΔEGFR. Journal of Proteome Research. 2011; 10: 1343-1352.
122. Kozlova N, Samoylenko A, Drobot L, and Kietzmann T. Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231. Molecular Carcinogenesis. 2015: n/a-n/a.
123. Wasylyk B, Hagman J, and Gutierrez-Hartmann A. Ets transcription factors: nuclear effectors of the Ras-MAPkinase signaling pathway. Trends in Biochemical Sciences. 1998; 23: 213-216.
124. Turner DP, Findlay VJ, Kirven AD, Moussa O, and Watson DK. Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Molecular Biology of the Cell. 2008; 19: 3745-3757.
125. Galang CK, García-Ramírez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, Oshima RG, and Hauser CA. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neumediated cellular transformation. Journal of Biological Chemistry. 1996; 271: 7992-7998.
126. Shepherd T and Hassell JA. Role of Ets transcription factors in mammary gland development and oncogenesis. Journal of Mammary Gland Biology and Neoplasia 2001; 6: 129-140.
127. Sharrocks AD. The ETS-domain transcription factor family. Nature Reviews Molecular Cell Biology. 2001; 2: 827-837.
128. Lindermann RK, Braig M, Ballschmieter P, Guise TA, Nordheim A, and Dittmer J. Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. International Journal of Oncology. 2003; 22: 799-805.
129. Vetter M, Blumenthal SG, Lindemann RK, Manns J, Wesselborg S, Thomssen C, and Dittmer J. Ets1 is an effector of protein kinase Calpha in cancer cells. Oncogene. 2005; 24: 650-661.
130. Tetreault MP, Yang Y, Travis J, Yu QC, Klein-Szanto A, Tobias JW, and Katz JP. Esophageal squamous cell dysplasia and delayed differentiation with deletion of kruppel-like factor 4 in murine esophagus. Gastroenterology. 2010; 139: 171-181.
131. Limame R, Op de Beeck K, Lardon F, De Wever O, and Pauwels P. Krüppel-like factors in cancer progression: three fingers on the steering wheel. Oncotarget. 2014; 5: 29-48.
132. Bureau C, Hanoun N, Torrisani J, Vinel JP, Buscail L, and Cordelier P. Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Current Genomics. 2009; 10: 353-360.
133. Tetreault MP, Yang Y, and Katz JP. Krüppel-like factors in cancer. Nature Reviews Cancer. 2013; 13: 701-713.
134. Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, and Ruppert JM. Increase of GKLF Messenger RNA and Protein Expression during Progression of Breast Cancer. Cancer Research. 2000; 60: 6488-6495.
135. Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI, LoBuglio AF, Lobo-Ruppert SM, et al. Nuclear Localization of KLF4 Is Associated with an Aggressive Phenotype in Early-Stage Breast Cancer. Clinical Cancer Research. 2004; 10: 2709-2719.
136. Wang X, Zheng M, Liu G, Xia W, McKeown-Longo PJ, Hung MC, and Zhao J. Kruppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Research. 2007; 67: 7184-7193.
137. Wang X, Lu H, Urvalek AM, Li T, Yu L, Lamar J, DiPersio CM, Feustel PJ, and Zhao J. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene. 2011; 30: 1901-1911.
138. Jin W, Chen BB, Li JY, Zhu H, Huang M, Gu SM, Wang QQ, Chen JY, Yu S, Wu J, and Shao ZM. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Molecular and Cellular Biology. 2012; 32: 50-63.
139. Subramaniam M, Hefferan TE, Tau K, Peus D, Pittelkow M, Jalal S, Riggs BL, Roche P, and Spelsberg TC. Tissue, cell type, and breast cancer stage-specific expression of a TGF-beta inducible early transcription factor gene. Journal of Cellular Biochemistry. 1998; 68: 226-236.
140. Chen C, Bhalala HV, Qiao H, and Dong JT. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene. 2002; 21: 6567-6572.
141. Tong D, Czerwenka K, Heinze G, Ryffel M, Schuster E, Witt A, Leodolter S, and Zeillinger R. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clinical Cancer Research. 2006; 12: 2442-2448.
142. Liu J, Du T, Yuan Y, He Y, Tan Z, and Liu Z. KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway. Molecular and Cellular Biochemistry. 2010; 335: 29-35.
143. Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, and Jacot W. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Research. 2011; 13: R15.
144. Uhr J. uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues. Breast Care (Basel). 2008; 3: 16-19.
145. Zhang L, Ridgway LD, Wetzel MA, Ngo J, Yin W, Kumar D, Goodman JC, Groves MD, and Marchetti D. The identification and characterization of breast cancer CTCs competent for brain metastasis. Science Translational Medicine. 2013; 5.
146. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, et al. Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis. Cell. 2014; 158: 1110-1122.
147. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, and Winn RJ. Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers. Journal of the National Cancer Institute. 1996; 88: 1456-1466.
148. Thomssen C and Jänicke F. Do we need better prognostic factors in node-negative breast cancer? European Journal of Cancer. 2000; 36: 293-298.
149. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, and Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. International Journal of Cancer. 1995; 61: 597-600.
150. Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, and Stroebel P. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histology and Histopathology. 2009; 24: 869-877.
151. Harbeck N, Ross JS, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, and Schmitt M. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. International Journal of Oncology. 1999; 14: 663-734.
152. Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, and Pegram M. HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer. Clinical Cancer Research. 2001; 7: 2448-2457.
153. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, and Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in nodenegative breast cancer. Breast Cancer Research and Treatment. 1993; 24: 195-208.
154. Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IbJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CGJF, Ulm K, Peyrat J-P, et al. Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients. Journal of the National Cancer Institute. 2002; 94: 116-128.
155. Witzel I, Milde-Langosch K, Schmidt M, Karn T, Rody A, Wirtz R, Jänicke F, and Müller V. Abstract P6-06-44: Role of uPA and PAI-1 mRNA expression as prognostic factors in molecular subtypes of breast cancer. Cancer Research. 2013; 73: P6-06-44.
156. Duffy MJ, McGowan PM, Harbeck N, Thomssen C, and Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Research. 2014; 16: 428.
157. Li C, Cao S, Liu Z, Ye X, Chen L, and Meng S. RNAimediated downregulation of UPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. International Journal of Cancer. 2010; 127: 1507-1516.
158. Fidler IJ and Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science. 1977; 197: 893-895.
159. Giavazzi R, Alessandri G, Spreafico F, Garattini S, and Mantovani A. Metastasizing capacity of tumor cells from spontaneous metastases of transplanted murine tumors. British Journal of Cancer 1980; 42: 462-472.
160. Mantovani A, Giavazzi R, Alessandri G, Spreafico F, and Garattini S. Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma. European Journal of Cancer 1981; 17: 71-76.
161. Milas L, Peters LJ, and Ito H. Spontaneous metastasis: random or selective? Clinical and Experimental Metastasis. 1983; 1: 309-315.
162. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530-536.
163. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, et al. A geneexpression signature as a predictor of survival in breast cancer. New England Journal of Medicine. 2002; 347: 1999-2009.
164. Ramaswamy S, Ross KN, Lander ES, and Golub TR. A molecular signature of metastasis in primary solid tumors. Nature Genetics. 2003; 33: 49-54.
165. Bernards R and Weinberg RA. A progression puzzle. Nature. 2002; 418: 823.